55 minutes ago
Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.
2 hours ago
Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.
3 hours ago
FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.
3 hours ago
Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.
4 hours ago
A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency.